Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone512-869-1555
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.28 million
Profitability
Miscellaneous
Employees68
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions
What is Molecular Templates' stock symbol?
Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."
When did Molecular Templates' stock split? How did Molecular Templates' stock split work?
Molecular Templates shares reverse split on the morning of Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.
How were Molecular Templates' earnings last quarter?
Molecular Templates Inc (NASDAQ:MTEM) issued its quarterly earnings data on Monday, May, 13th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.05. The biotechnology company had revenue of $7.01 million for the quarter, compared to analyst estimates of $6 million. Molecular Templates had a negative net margin of 42.15% and a negative return on equity of 9.14%. View Molecular Templates' Earnings History.
When is Molecular Templates' next earnings date?
What price target have analysts set for MTEM?
7 analysts have issued 12 month target prices for Molecular Templates' stock. Their predictions range from $12.00 to $18.00. On average, they expect Molecular Templates' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 92.6% from the stock's current price. View Analyst Price Targets for Molecular Templates.
What is the consensus analysts' recommendation for Molecular Templates?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Molecular Templates.
What are Wall Street analysts saying about Molecular Templates stock?
Here are some recent quotes from research analysts about Molecular Templates stock:
- 1. According to Zacks Investment Research, "Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered in Austin, United States. " (4/2/2019)
- 2. LADENBURG THALM/SH SH analysts commented, "Initiating coverage with Outperform rating and $15 PT. We believe Bodies (ETB) platform offers a differentiated MOA based on forced internalization of antibody fragments directly to ribosomes through the Shiga-Like toxin A mechanism of action resulting in disruption of protein synthesis and direct cell-kill. We expect this novel MOA to offer clinical advantages in: 1) monotherapy in refractory setting when receptor expression is maintained despite resistance to prior treatments targeting the receptor (i.e., 2) combination therapy for frontline as a more potent substitute for a antibody therapeutics, and 3) novel targets not amenable to antibodies due to challenges to internalization. We anticipate ETBs will be attractive to pharma and expect partnerships to contribute to 2019-20 news flow." (12/10/2018)
Has Molecular Templates been receiving favorable news coverage?
Headlines about MTEM stock have trended neutral recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Molecular Templates earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Molecular Templates' key competitors?
Some companies that are related to Molecular Templates include Turning Point Therapeutics (TPTX), Theravance Biopharma (TBPH), Eidos Therapeutics (EIDX), Amphastar Pharmaceuticals (AMPH), Clementia Pharmaceuticals (CMTA), Inflarx (IFRX), Ra Pharmaceuticals (RARX), Deciphera Pharmaceuticals (DCPH), Radius Health (RDUS), Athenex (ATNX), Homology Medicines (FIXX), Alder Biopharmaceuticals (ALDR), Omeros (OMER), Rhythm Pharmaceuticals (RYTM) and Axovant Sciences (AXON).
What other stocks do shareholders of Molecular Templates own?
Who are Molecular Templates' key executives?
Molecular Templates' management team includes the folowing people:
- Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 47)
- Ms. Jason S Kim, Pres & COO (Age 44)
- Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 44)
- Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)
- Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 39)
Who are Molecular Templates' major shareholders?
Molecular Templates' stock is owned by a number of of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.74%), Gilder Gagnon Howe & Co. LLC (2.66%), BlackRock Inc. (1.95%), Prosight Management LP (0.81%), Northern Trust Corp (0.46%) and Fosun International Ltd (0.44%). Company insiders that own Molecular Templates stock include Associates LLC Cdk, David Hirsch, Jeffrey W Bird and Scott D Morenstein. View Institutional Ownership Trends for Molecular Templates.
Which institutional investors are selling Molecular Templates stock?
MTEM stock was sold by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, JPMorgan Chase & Co., BlackRock Inc., Morgan Stanley, Gilder Gagnon Howe & Co. LLC, Wells Fargo & Company MN and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Molecular Templates.
Which institutional investors are buying Molecular Templates stock?
MTEM stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, BVF Inc. IL, Fosun International Ltd, Dimensional Fund Advisors LP, Private Advisors LLC, Renaissance Technologies LLC, Marshall Wace LLP and State of Wisconsin Investment Board. Company insiders that have bought Molecular Templates stock in the last two years include Associates LLC Cdk, David Hirsch, Jeffrey W Bird and Scott D Morenstein. View Insider Buying and Selling for Molecular Templates.
How do I buy shares of Molecular Templates?
Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Molecular Templates' stock price today?
One share of MTEM stock can currently be purchased for approximately $7.79.
How big of a company is Molecular Templates?
Molecular Templates has a market capitalization of $286.43 million and generates $13.28 million in revenue each year. The biotechnology company earns $-30,290,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Molecular Templates employs 68 workers across the globe.
What is Molecular Templates' official website?
How can I contact Molecular Templates?
Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]
MarketBeat Community Rating for Molecular Templates (NASDAQ MTEM)
MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote "Outperform" if you believe MTEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
